Annual CFO
-$48.96 M
+$7.33 M+13.01%
31 December 2023
Summary:
Silence Therapeutics annual cash flow from operations is currently -$48.96 million, with the most recent change of +$7.33 million (+13.01%) on 31 December 2023. During the last 3 years, it has fallen by -$35.13 million (-254.03%). SLN annual CFO is now -622.94% below its all-time high of $9.36 million, reached on 31 December 2021.SLN Cash From Operations Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Quarterly CFO
-$26.06 M
-$20.04 M-332.69%
01 September 2024
Summary:
Silence Therapeutics quarterly cash flow from operations is currently -$26.06 million, with the most recent change of -$20.04 million (-332.69%) on 01 September 2024. Over the past year, it has dropped by -$19.56 million (-301.03%). SLN quarterly CFO is now -172.09% below its all-time high of $36.15 million, reached on 30 June 2021.SLN Quarterly CFO Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
TTM CFO
-$55.76 M
-$19.56 M-54.06%
01 September 2024
Summary:
Silence Therapeutics TTM cash flow from operations is currently -$55.76 million, with the most recent change of -$19.56 million (-54.06%) on 01 September 2024. Over the past year, it has dropped by -$2.38 million (-4.46%). SLN TTM CFO is now -386.19% below its all-time high of $19.48 million, reached on 30 June 2021.SLN TTM CFO Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
SLN Cash From Operations Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | +13.0% | -301.0% | -4.5% |
| 3 y3 years | -254.0% | -269.3% | -548.8% |
| 5 y5 years | -119.0% | - | - |
SLN Cash From Operations High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3 years | -622.9% | +13.0% | -751.5% | at low | -548.8% | +0.9% |
| 5 y | 5 years | -622.9% | +13.0% | -172.1% | at low | -386.2% | +0.9% |
| alltime | all time | -622.9% | +13.0% | -172.1% | at low | -386.2% | +0.9% |
Silence Therapeutics Cash From Operations History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sept 2024 | - | -$26.06 M(+332.7%) | -$55.76 M(+54.1%) |
| June 2024 | - | -$6.02 M(-36.6%) | -$36.19 M(-26.4%) |
| Mar 2024 | - | -$9.51 M(-32.9%) | -$49.16 M(+0.4%) |
| Dec 2023 | -$48.96 M(-13.0%) | -$14.16 M(+117.9%) | -$48.96 M(-8.3%) |
| Sept 2023 | - | -$6.50 M(-65.8%) | -$53.37 M(-4.9%) |
| June 2023 | - | -$19.00 M(+104.1%) | -$56.13 M(+21.2%) |
| Mar 2023 | - | -$9.31 M(-49.9%) | -$46.31 M(-17.7%) |
| Dec 2022 | -$56.29 M(-701.2%) | -$18.57 M(+100.8%) | -$56.29 M(+38.0%) |
| Sept 2022 | - | -$9.25 M(+0.8%) | -$40.78 M(+5.7%) |
| June 2022 | - | -$9.18 M(-52.4%) | -$38.59 M(-672.0%) |
| Mar 2022 | - | -$19.29 M(+530.1%) | $6.75 M(-28.0%) |
| Dec 2021 | $9.36 M(-167.7%) | -$3.06 M(-56.6%) | $9.36 M(-24.6%) |
| Sept 2021 | - | -$7.06 M(-119.5%) | $12.42 M(-36.2%) |
| June 2021 | - | $36.15 M(-316.9%) | $19.48 M(-216.9%) |
| Mar 2021 | - | -$16.67 M | -$16.67 M |
| Dec 2020 | -$13.83 M(-727.2%) | - | - |
| Dec 2019 | $2.21 M(-109.9%) | - | - |
| Dec 2018 | -$22.36 M(+80.4%) | - | - |
| Dec 2017 | -$12.39 M(-9.1%) | - | - |
| Dec 2016 | -$13.64 M(+8.1%) | - | - |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Dec 2015 | -$12.62 M(-19.1%) | - | - |
| Dec 2014 | -$15.59 M(+47.5%) | - | - |
| Dec 2013 | -$10.57 M(+36.8%) | - | - |
| Dec 2012 | -$7.73 M(-5.5%) | - | - |
| Dec 2011 | -$8.17 M(-49.7%) | - | - |
| Dec 2010 | -$16.26 M(+123.4%) | - | - |
| Dec 2009 | -$7.28 M(-43.6%) | - | - |
| Dec 2008 | -$12.91 M(+68.3%) | - | - |
| Dec 2007 | -$7.67 M(+3.2%) | - | - |
| Dec 2006 | -$7.43 M(+46.8%) | - | - |
| Dec 2005 | -$5.06 M(+17.7%) | - | - |
| Dec 2004 | -$4.30 M(+29.3%) | - | - |
| Dec 2003 | -$3.33 M(+20.3%) | - | - |
| Dec 2002 | -$2.77 M(-15.9%) | - | - |
| Dec 2001 | -$3.29 M(-24.1%) | - | - |
| Dec 2000 | -$4.33 M(+136.2%) | - | - |
| Dec 1999 | -$1.83 M(-38.7%) | - | - |
| Dec 1998 | -$2.99 M(+20.3%) | - | - |
| Dec 1997 | -$2.49 M(+119.2%) | - | - |
| Dec 1996 | -$1.14 M(-5.5%) | - | - |
| Dec 1995 | -$1.20 M | - | - |
FAQ
- What is Silence Therapeutics annual cash flow from operations?
- What is the all time high annual CFO for Silence Therapeutics?
- What is Silence Therapeutics annual CFO year-on-year change?
- What is Silence Therapeutics quarterly cash flow from operations?
- What is the all time high quarterly CFO for Silence Therapeutics?
- What is Silence Therapeutics quarterly CFO year-on-year change?
- What is Silence Therapeutics TTM cash flow from operations?
- What is the all time high TTM CFO for Silence Therapeutics?
- What is Silence Therapeutics TTM CFO year-on-year change?
What is Silence Therapeutics annual cash flow from operations?
The current annual CFO of SLN is -$48.96 M
What is the all time high annual CFO for Silence Therapeutics?
Silence Therapeutics all-time high annual cash flow from operations is $9.36 M
What is Silence Therapeutics annual CFO year-on-year change?
Over the past year, SLN annual cash flow from operations has changed by +$7.33 M (+13.01%)
What is Silence Therapeutics quarterly cash flow from operations?
The current quarterly CFO of SLN is -$26.06 M
What is the all time high quarterly CFO for Silence Therapeutics?
Silence Therapeutics all-time high quarterly cash flow from operations is $36.15 M
What is Silence Therapeutics quarterly CFO year-on-year change?
Over the past year, SLN quarterly cash flow from operations has changed by -$19.56 M (-301.03%)
What is Silence Therapeutics TTM cash flow from operations?
The current TTM CFO of SLN is -$55.76 M
What is the all time high TTM CFO for Silence Therapeutics?
Silence Therapeutics all-time high TTM cash flow from operations is $19.48 M
What is Silence Therapeutics TTM CFO year-on-year change?
Over the past year, SLN TTM cash flow from operations has changed by -$2.38 M (-4.46%)